Logo Logo
Hilfe
Hilfe
Switch Language to English

Westphalen, C. Benedikt; Kruger, Stephan; Haas, Michael; Heinemann, Volker und Boeck, Stefan (2016): Safety of palliative chemotherapy in advanced pancreatic cancer. In: Expert Opinion On Drug Safety, Bd. 15, Nr. 7: S. 947-954

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Introduction: Pancreatic cancer is a major health burden. Currently, the majority of patients is diagnosed at advanced stages and thus qualifies for palliative chemotherapy. Gemcitabine monotherapy has been the gold standard for many years. Recently, more effective chemotherapeutic regimens have shown meaningful clinical activity in patients with metastatic pancreatic cancer. Areas covered: In this review we have aimed to give an overview on the treatment options for patients diagnosed with metastatic pancreatic cancer with an emphasis on the safety and toxicity of the applied regimens. We have conducted a pubmed search using the terms 'metastatic pancreatic cancer', 'palliative chemotherapy', 'safety' and 'toxicity'. Our special focus rested on randomized phase III trials to provide readers with the highest level of available evidence. Expert opinion: The emergence of new and more effective chemotherapy regimens gives clinicians more freedom in the treatment of metastatic pancreatic cancer. While being more effective, these regiments have a considerable degree of toxicity. Choosing the right treatment for any individual will be the next major challenge treating patients with pancreatic cancer.

Dokument bearbeiten Dokument bearbeiten